SteelPeak Wealth LLC grew its stake in Astrana Health, Inc. (NASDAQ:ASTH - Free Report) by 4.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 568,176 shares of the company's stock after buying an additional 26,192 shares during the quarter. SteelPeak Wealth LLC owned 1.13% of Astrana Health worth $17,619,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in ASTH. 325 Capital LLC boosted its holdings in shares of Astrana Health by 30.3% in the fourth quarter. 325 Capital LLC now owns 886,916 shares of the company's stock valued at $27,964,000 after buying an additional 206,009 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Astrana Health by 217.6% in the fourth quarter. Renaissance Technologies LLC now owns 217,900 shares of the company's stock valued at $6,870,000 after buying an additional 149,300 shares during the period. Royce & Associates LP boosted its holdings in shares of Astrana Health by 122.3% in the fourth quarter. Royce & Associates LP now owns 255,552 shares of the company's stock valued at $8,058,000 after buying an additional 140,584 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Astrana Health by 10.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,045,540 shares of the company's stock valued at $32,968,000 after buying an additional 101,192 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Astrana Health by 136.1% in the fourth quarter. JPMorgan Chase & Co. now owns 163,532 shares of the company's stock valued at $5,156,000 after buying an additional 94,268 shares during the period. Institutional investors and hedge funds own 52.77% of the company's stock.
Astrana Health Stock Up 0.9%
ASTH traded up $0.22 during trading hours on Monday, hitting $25.12. 304,041 shares of the company's stock were exchanged, compared to its average volume of 296,328. Astrana Health, Inc. has a 1-year low of $23.12 and a 1-year high of $63.20. The stock's 50-day moving average is $25.99 and its two-hundred day moving average is $30.39. The stock has a market cap of $1.41 billion, a price-to-earnings ratio of 34.89, a PEG ratio of 0.91 and a beta of 0.84. The company has a quick ratio of 1.70, a current ratio of 1.70 and a debt-to-equity ratio of 0.54.
Astrana Health (NASDAQ:ASTH - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.09). Astrana Health had a return on equity of 4.90% and a net margin of 1.56%. The firm had revenue of $620.39 million for the quarter, compared to the consensus estimate of $628.11 million. During the same period last year, the company posted $0.31 earnings per share. The business's revenue was up 53.4% compared to the same quarter last year. Sell-side analysts predict that Astrana Health, Inc. will post 1.15 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
ASTH has been the subject of several research analyst reports. Truist Financial reduced their price target on shares of Astrana Health from $50.00 to $46.00 and set a "buy" rating for the company in a report on Tuesday, March 18th. Barclays assumed coverage on shares of Astrana Health in a report on Tuesday, April 1st. They set an "equal weight" rating and a $36.00 target price for the company. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $53.29.
Get Our Latest Analysis on Astrana Health
About Astrana Health
(
Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
See Also
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
